TKPHF TAKEDA PHARMACEUTICAL CO LTD

NEUTRAL Impact: 5/10 6-K
Horizon weeks Filed May 26, 2026 Processed 15d 8h ago SEC 0001395064-26-000160
Notable filing: 6-K
Latest settled — T+5d ⚠ clustered
TKPHF ▼ -5.08% at T+5d
NEUTRAL call ✗ call lost -5.08% · α vs SPY -6.29% · entry $32.10 → $30.47
Next anchor: T+20d in 14d
Currently $31.30 · -2.49% from $32.10 entry
Entry anchored
May 26, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.01%
$32.10
settled 14d ago
T+5d
-5.08%
call -5.08% · α -6.29%
$30.47
settled 8d ago
T+20d
call — · α —
in 14d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Takeda filed its annual report (FY ended March 31, 2026) via Form 6-K, disclosing total revenue of JPY 4,505,720 million and basic EPS of JPY 121.75. The filing includes JPY 129,266 million in impairment losses, including JPY 58,173 million from discontinuing cell therapy research and JPY 31,877 million related to ALUNBRIG, plus JPY 70,818 million in restructuring expenses. The filing also notes ongoing patent revocation proceedings for ENTYVIO in the UK and Netherlands, and a DOJ investigation into TRINTELLIX marketing practices. No prior-year comparative financials are provided, preventing YoY growth analysis.

Actionable Insight

Monitor upcoming patent litigation outcomes for ENTYVIO, which generated JPY 958,042 million in revenue (21% of total), as adverse rulings could materially impact future sales. Track resolution of the DOJ investigation into TRINTELLIX marketing practices for potential financial penalties.

Key Facts

  • Total revenue for FY ended March 31, 2026: JPY 4,505,720 million
  • Basic EPS: JPY 121.75
  • Impairment losses of JPY 129,266 million, including JPY 58,173 million from discontinuing gamma delta T-cell therapy platform and JPY 31,877 million related to ALUNBRIG
  • Restructuring expenses of JPY 70,818 million from enterprise-wide efficiency program
  • Goodwill of JPY 5,809,010 million and intangible assets of JPY 3,419,348 million on balance sheet
  • Patent revocation proceedings initiated against ENTYVIO patents in UK and Netherlands (Feb-Apr 2026)
  • DOJ Civil Investigative Demand regarding TRINTELLIX off-label promotion and Anti-Kickback Statute violations
  • Share buyback completed: 23,367 thousand shares for JPY 99,956 million
  • Proposed dividend of JPY 100.00 per share for record date March 31, 2026
  • No prior-year comparative financial data provided in this filing

Financial Impact

Revenue JPY 4,505,720 million; EPS JPY 121.75; impairments JPY 129,266 million; restructuring JPY 70,818 million

revenueepsimpairment lossesrestructuring costs

Risk Factors

  • ENTYVIO patent revocation proceedings in UK and Netherlands could threaten key revenue driver
  • DOJ investigation into TRINTELLIX off-label promotion may result in penalties or compliance costs
  • Large goodwill and intangible asset base (JPY 9.2 trillion combined) exposes balance sheet to future impairment risk
  • Ongoing restructuring program may indicate persistent cost pressures

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (19 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000160
Document: form6k_052626x2.htm0001395064-26-000160
Document: 0001395064-26-000160-index-headers.html0001395064-26-000160
Document: 0001395064-26-000160-index.html0001395064-26-000160
Document: 0001395064-26-000160.txt0001395064-26-000160
10 reports for TKPHF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TKPHF — sortable, filterable
Type Now
Jun 9, 2026
1d ago
6-K
NEUTRAL ★ 3/10
awaiting T+5
Jun 5, 2026
5d ago
6-K
BEARISH ★ 6/10
$30.47 awaiting T+5awaiting T+5$31.30 (−2.72%)
Jun 5, 2026
5d ago
6-K
BEARISH ★ 6/10
$30.47 awaiting T+5awaiting T+5$31.30 (−2.72%)
Jun 1, 2026
9d ago
6-K
NEUTRAL ★ 2/10
$30.47 $30.47· 0.00%▲ +2.75%$31.30 (+2.72%)
May 26, 2026
15d ago
6-K
MIXED ★ 6/10
$32.10 $30.47▼ −5.08%▼ −6.29%$31.30 (−2.49%)
May 26, 2026
15d ago
6-K
NEUTRAL ★ 5/10
$32.10 $30.47▼ −5.08%▼ −6.29%$31.30 (−2.49%)
May 26, 2026
15d ago
6-K
MIXED ★ 6/10
$32.10 $30.47▼ −5.08%▼ −6.29%$31.30 (−2.49%)
May 26, 2026
15d ago
6-K
BEARISH ★ 6/10
$32.10 $30.47▲ +5.08%▲ +6.29%$31.30 (+2.49%)
May 19, 2026
22d ago
6-K
BEARISH ★ 8/10
$32.26 $32.10▲ +0.50%▲ +2.79%$31.30 (+2.98%)
May 13, 2026
28d ago
6-K
NEUTRAL ★ 2/10
$32.68 $32.26▼ −1.29%▼ −0.13%$31.30 (−4.22%)
Showing 10 of 10

US Market Status

Market Open — Closes in 1h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access